The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The TALISMAN study: prophylactic treatment for talquetamab-related oral toxicity in myeloma
Taste disturbances, known as dysgeusia, are a common side effect of talquetamab treatment and significantly impact the quality of life (QoL) of many patients. Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares insight into the Phase II TALISMAN study (NCT06500884), which will evaluate prophylactic treatments for talquetamab-related oral toxicity in patients with relapsed/refractory (R/R) multiple myeloma (MM). The therapeutic strategies that will be tested are dexamethasone mouthwash, oral pregabalin, and clonazepam orally dissolving tablets. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
